How a newly discovered mast cell receptor affects allergic reactions and skin inflammation
Official title: Roles of novel MRGPRX2/MrgprB2 signaling in mast cells on host defense and Inflammation
Funded at University of Pennsylvania · NIH-11305722 · Data updated 2026-11-12
Researchers want to see if a newly found mast cell receptor controls allergy reactions and skin inflammation to help people with drug allergies, anaphylaxis, or chronic skin problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pennsylvania NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project start | December 1, 2019 |
| Project end | January 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $1,909,388 |
| NIH project number | 2R01AI149487-06 |
| Project ID | NIH-11305722 on NIH RePORTER |
Who could benefit from this research
✓Could help
People with a history of immediate drug hypersensitivity reactions, unexplained anaphylaxis, recurrent mast cell–related skin conditions, or chronic inflammatory skin disease may be relevant to this line of work.
✕Less likely to help
Patients whose problems are not driven by mast cells or MRGPRX2-related pathways (for example many autoimmune or purely neurological conditions) are unlikely to benefit directly from these findings.
What this research studies
This work looks at a receptor called MRGPRX2 (and its mouse counterpart MrgprB2) that turns on mast cells, which are immune cells involved in allergies and skin inflammation. Scientists will use human mast cells in the lab, reduce the activity of specific signaling proteins (G proteins and GRK2), and measure how the receptor reacts to drugs and peptides. They will also use mouse models engineered to express the receptor to study whole-body responses like anaphylaxis and skin inflammation. The goal is to understand the signaling steps that make mast cells trigger harmful reactions so new, safer treatment approaches can be designed.
Why it matters
Potential benefit: If successful, this could point to new ways to prevent or treat immediate drug allergies, anaphylaxis, and certain inflammatory skin conditions by targeting receptor signaling.
How similar studies have gone: Some small molecules that block MRGPRX2 have been developed but a recent clinical candidate encountered toxicity in phase 2, so targeting interacting proteins like G proteins or GRK2 is a newer and less-tested approach.
Where this research is happening
-
University of Pennsylvania
Philadelphia, United States Active
Researchers
- Principal investigator: Ali, Hydar — University of Pennsylvania
- Study coordinator: Ali, Hydar
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.